The FDA is considering a second COVID-19 booster dose of the mRNA COVID-19 vaccines; use of the unproven COVID-19 therapies hydroxychloroquine and ivermectin has been significantly greater in the highest vs lowest Republican vote share counties; infertility treatments associated with vascular and pregnancy-related complications.
The Wall Street Journal reported that the FDA is “very carefully” considering whether a second COVID-19 booster dose of the mRNA COVID-19 vaccines would be warranted this Fall. Potentially coinciding with the typical administration of annual flu shots, FDA officials noted that the decision will be based on emerging data regarding the pandemic, safety and efficacy of booster vaccines, and the presence of variants in the United States and overseas. Currently, second booster doses are approved in Sweden for those over the age of 80 and in Israel for certain citizens, which may be expanded to all adults.
A study published recently in JAMA Internal Medicine showed that use of the unproven COVID-19 therapies hydroxychloroquine and ivermectin was significantly greater in the most populated Republican counties vs least populated. According to the The Hill, prescribing volume from June through December 2020 for hydroxychloroquine was 146% higher in the highest vs lowest Republican vote share counties than what it had been the previous year, with the volume of ivermectin prescriptions indicated to be 964% higher during this time as well.
Findings of a study published today in the Journal of the American Heart Association showed that women who used assisted reproductive technology to get pregnant may be at increased risk for vascular and pregnancy-related complications, particularly those aged 35 and older. Reported by CNN, analyses of 106,248 deliveries in which the baby was conceived with assisted reproductive technology compared with more than 34 million births conceived without such aid indicated that those who used the infertility treatments were at 2.5 times greater risk of acute kidney failure and 65% more likely to have an irregular heartbeat. Women who used the treatments were noted to have had more preexisting health conditions, such as high blood pressure and diabetes, as well as greater incidence of obesity when starting treatment.
Review Emphasizes Potential Infection Risks With BTK Inhibitors
November 2nd 2024Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
PAH Treatment Outcomes Similar Regardless of Diagnosis Time
November 1st 2024The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
Read More